Clinical Trial Update: JNJ-40346527 in Treating Participants With Relapsed or Refractory Acute Myeloid Leukemia [Phase 2]

View source ↗

Summary

Phase 2 clinical trial of JNJ-40346527 in relapsed or refractory acute myeloid leukemia has terminated with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• JNJ-40346527

Snippet

Sponsor: OHSU Knight Cancer Institute | Conditions: Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia | Phase 2 | Status: TERMINATED | Results posted: 2021-12-02